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HLA, atopy, and cyclophosphamide in steroid-responsive child-
hood nephrotic syndrome. In a study designed to confirm our pre-
liminary report of associations between HLA-B12, atopy, and
relapse following cyclophosphamide treatment in steroid-respon-
sive nephrotic syndrome (SRNS), we again found a higher in-
cidence of H LA-B 12 in SRNS children (44%) than we did in con-
trols (24%). The association of HLA-B12 with short time-to-re-
lapse after cyclophosphamide treatment of SRNS was also
confirmed, but that with atopy in SRNS children was not, though
we observed a similarly high incidence of atopy in them as be-
fore.
HLA, atopie, et cyclophosphamide au cours du syndrome
néphrotique cortico sensible de l'enfant. Au cours d'une étude
destinée a confirmer notre observation préliminaire d'asso-
ciations entre HLA-B12, atopie et récidive après traitement
par le cyclophosphamide du syndrome néphrotique cortico
sensible (SRNS) nous avons a nouveau constaté une frequence
plus élevée de HLA-Bl2 chez les enfants atteints de SRNS
(44%) que chez les contrôles (24%). L'association de HLA-B12
avec des récidives a court terme après traitement par le cyclo-
phosphamide de SNRS a aussi été comfirmée, mais celle avec
l'atopie chez les enfants SNRS ne l'a pas été, bien que nous
ayons observe Ia méme incidence élevée d'atopie chez ces sujets
qu'auparavant.
We have reported previously that the steroid-re-
sponsive nephrotic syndrome (SRNS) of childhood
is associated both with atopy and with HLA-B12,
and that SRNS children with HLA-Bl2 have a high-
er incidence of atopy and a greater tendency to
early relapse after cyclophosphamide treatment
than those without HLA-B12 [1]. To explore the in-
teraction of HLA-Bl2 and the response to cyclo-
phosphamide therapy more fully, we recalled for
tissue-typing the SRNS children treated by us with
cyclophosphamide during 1966 to 1974; they have
been described elsewhere [2]. In doing so, we ob-
tained a second group of SRNS children in whom
we could independently confirm our previous ob-
servations on the incidence of HLA-B12, avoiding
the statistical uncertainties that arise when the in-
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cidence of a wide range of HLA antigens is investi-
gated [3].
Methods
The SRNS children consisted of two overlapping
series: 71 children in group A were consecutive out-
patient attenders during 1974 to 1975 and were stud-
ied for HLA type and atopy [1], whereas group B
consisted of the 81 SRNS children who were treated
with an 8-week course of cyclophosphamide (3 mgI
kg of body wt per day) at The Hospital for Sick
Children, London, during 1966 to 1974 [2]. We re-
called group B and studied 72 of them (7 were
abroad and 2 were untraceable); all were in remis-
sion and off treatment at the time of study, and had
completed their cyclophosphamide treatment
course at least 3 years beforehand. Of these 72 chil-
dren, 27 had been included previously in group A,
but the remaining 45 constitute a new series (group
B') from the point of view of HLA type and atopy,
though IgE and IgE antibody data were incomplete
in 2 of them. The definitions used for nephrotic syn-
drome, relapse, and so on have been published pre-
viously [1, 2].
Atopy (hay fever, eczema, and asthma) was as-
certained by questionnaire [1]. Skin-prick tests
were done with Dermatophagoides pleronyssinus,
mixed grass pollen, Timothy grass pollen, cat fur,
Aspergilius fumigatus, cow's milk, and control
(Bencard®); wheal diameter was measured. A
wheal greater than 1 mm to any antigen with nega-
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Table 1. Frequency of HLA-B12 in children with steroid-responsive nephrotic syndrome
Group A [I] Group B' Combined British blood donors[41
HLA-B12 38/71 20/45 58/116 254/1036
(54%) (44%) (50%) (24%)
x2c vs. blood donors 27.3 8,0 — —
P <0.02 <0.005 — —
aCoffected for 23 antigens compared
Table 2. Relation between HLA-Bl2 and atopic features in children with steroid-responsive nephrotic syndrome
Group A (I) Group B' Combined
HLA-B12 HLA-B12 HLA-B12
+ — Total + — Total + — Total
Atopic history 13/35 1/30 14/65 3/20 8/25 11/45 16/55 9/55 25/11
(37%) (3%) (21%) (15%) (32%) (24%) (29%) (16%) (23%)
Total IgE >150 lU/mI 13/29 3/21 16/50 3/18 8/25 11/43 16/47 11/46 27/93
(48%) (13%) (32%) (17%) (32%) (26%) (34%) (24%) (29%)
Prick test positive
Grass pollen 10/31 2/25 12/56 2/20 10/25 12/45 12/51 12/50 24/101
(32%) (8%) (22%) (10%) (40%) (27%) (24%) (24%) (24%)
D. pier. 11/31 5/25 16/56 5/20 9/25 14/45 16/51 14/50 30/101
(35% (20%) (29%) (25%) (36%) (31%) (31%) (28%) (30%)
IgE antibody high
Grass pollen 9/29 2/21 11/50 4/18 9/25 13/43 13/47 11/46 24/93
(31%) (10%) (22%) (22%) (36%) (30%) (28%) (24%) (26%)
D. pier. 11/26 4/23 15/49 3/18 8/25 11/43 14/44 12/48 26/92
(42%) (17%) (30%) (17%) (32%) (26%) (34%) (25%) (28%)
tive control was classified as positive; all but two of
those positive to other antigens were also positive
to D. pter. or mixed grass pollen, or both, so analy-
ses were restricted to these two last antigens.
Serum IgE and IgE antibody to D. pter. and Tim-
othy grass pollen were measured as before [1].
Twenty-three HLA antigens were tested for by a
two-stage microtoxicity method with antisera pro-
vided by the National Organ Matching and Distribu-
tion Service, Bristol [4].
Results
HLA-B12. The frequency of HLA-B12 in the 45
SRNS children not previously tissue-types (group
B') was 44%, slightly lower than the 54% in the pre-
vious series (group A), but still significantly greater
(P < 0.005) than the 24% in the control group of
British blood donors [5] (Table I) (correction for the
number of antigens studied [3] was not necessary,
as the hypothesis tested was restricted to the fre-
quency of HLA-Bl2 alone). Combining the two se-
ries gave a frequency of HLA-B12 in SRNS chil-
dren of 50%, and thus the relative risk of SRNS in
children with HLA-l2 was 3.1 [6].
Atopy. Of group B' 24% had a positive atopic his-
tory on questionnaire; 26% had raised plasma total
IgE concentration (> 150 IU/ml); 27% had a posi-
tive prick test with mixed grass pollen, and 31%
with D. pter.; 28% had raised IgE antibody to Tim-
othy grass pollen, and 26% to D. pter. (data for IgE
tests not available for 2). Forty-four percent gave a
positive prick test, and 37% had raised IgE antibody
to one of both antigens: these figures are similar to
those observed previously in group A (Table 2).
There was a high correlation between skin test and
IgE antibody data for each antigen.
In group A, all four of the atopic features above
were significantly more frequent in SRNS children
with HLA-Bl2, but in the present series the trend
was reversed, significantly so (P < 0.05, exact test
[7]) for positive prick test to mixed grass pollen; in
the combined series no significant differences were
observed in the incidence of any of the four atopic
features in SRNS children with or without HLA-
B 12.
Relapse after cyclophospharnide. All 72 children
recalled in group B had a follow-up of at least 3
years after stopping cyclophosphamide treatment,
by which time 38 (53%) had relapsed (Table 3).
More (65%) of the 20 group B' SRNS children with
HLA-Bl2 relapsed within 3 years of cyclophospha-
mide treatment than did those of the 25 without
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Table 3. Relapse of steroid-responsive nephrotic synd rome inchildren within 3 years of cyclophosphamide treatment
Group A [I] Group B' Combined
HLA-B12 HLA-B12 HLA-B12
+ — Total + — Total + — Total
Relapse
P(exacttest)[71
10/12 4/15
(83%) (26%)
<0.01
14/27
(52%)
13/20 11/25
(65%) (44%)
>0.05
24/45
(53%)
23/32 15/40
(72%) (38%)
<0.01
38/72
(53%)
(45%) (Table 3); this difference is not significant as it
was in the 27 cyclophosphamide-treated children in
the group A series (83% and 26%; P < 0.01, exact
test), but it is significant for group B as a whole
(72% and 38%; P < 0.01). Of 18 children with an
atopic history, 12 (67%) relapsed in contrast to 23 of
54 (43%) without an atopic history on questionnaire
(Xtc = 2.69, P = 0.1); this trend is largely due to the
10 patients with eczema, of whom 8 (80%) relapsed
within 3 years. The time-to-relapse curve [8] was
plotted for the 81 cyclophosphamide-treated chil-
dren after adjustment for losses to follow-up: at the
end of the first year, 73% were still in remission; at
the end of the second year, 64% were in remission;
and at the end of the third year, 57% were in remis-
sion.
In the 69 group B children in whom the data were
complete, the effect on time-to-relapse of age, pres-
ence of HLA-B12, atopy symptoms, and positive
prick test were analyzed with Cox's regression and
Life Table model [9] (see Appendix). Children with
HLA-B12 relapsed sooner than did the others (P <
0.05) and those with atopy on questionnaire tended
to do so (0.05 < P < 0.10), whereas for age and
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prick tests no effect was detected. This analysis in-
dicates that HLA-B12 has a significant influence in
relapse after taking into account age, atopic history,
and presence of a positive skin test. The time-to-
relapse curves after cyclophosphamide in SRNS
children with and without HLA-B12 are shown in
Fig. 1.
Discussion
Studies reporting the association of a disease with
a feature such as HLA in which many antigens are
examined simultaneously require repeating in a sec-
ond series designed specifically to confirm the ob-
served association; the repeat study does not re-
quire correction of the probability value for the
number of characteristics studied [3]. Our second
series, reported here, confirms our previous obser-
vations of an increased frequency of HLA-B 12 in
nephrotic children: combining the series the fre-
quency observed was 50%, compared to 24% in
British blood donors. Meadow (personal communi-
cation), however, observed HLA-B 12 in only 34%
of 70 SRNS children and in 40% of those with one
or more relapse; these trends were not significantly
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Fig. 1. Time-to-relapse curves [9]for children with steroid-responsive nephrotic syndrome with (.) and without (o) HLA-B12.
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Appendix Table 1. Results of model-fitting assessing effects of independent variables on time-to-relapse
Estimated coefficients of independent
variables (with approximate SEM) Value
of logVariable /3 132 133 /34
omitted (age) (HLA-Bl2) (atopic history) (positive prick test) likelihood x2 statistic P
—
—0.077 0.838 0.856 —0.496
—133.636 — —
Age 0.895 0.959 0.590
—134.693 2.114 >0.10
HLA-Bl2 —0.093 1.002 —0.605
—
—136.577 5.882 <0.05
Atopy —0.090 0.928 —0.060
—
—135.468 3.644 0.05 <P <0.10
Prick test —0,087 0.885 0.560
—
—134.326 1.380 >0.10
different from the 31% in his controls. Our obser-
vation that HLA-B12 is associated with a tendency
to relapse may explain this difference because our
children were probably more frequent relapsers.
Perhaps HLA-Bl2 is related to the characteristic
determining relapse and not to the syndrome itself.
The presence of HLA-B12 is the strongest associ-
ation with relapse after cyclophosphamide therapy
that we have so far identified. There was also a
trend for atopic children, particularly those with ec-
zema, to relapse sooner than nonatopic children.
We previously reported that those treated when
older relapsed less readily [2], but this effect is
smaller in the present series, perhaps as a result of
the introduction of the new variables HLA-B12 and
atopy into the analysis.
In our previous study [1], we found a greater in-
cidence of atopic features in SRNS children with
HLA-B12 than we did in those without, but in the
present study the opposite trend was observed;
overall there was no association of atopy with
HLA-B12. We do not know why the two series dif-
fer: the patients were defined by clinical criteria,
but all those in whom histologic data were available
had only minimal histologic changes. The two series
were selected, however, by different criteria, the
first (series A) being consecutive clinic attenders,
and the second (series B) being selected for cyclo-
phosphamide therapy on the basis of frequent re-
lapses [2].
The pathogenesis of SRNS is not yet known, but
any hypothesis must account for the increased fre-
quency of HLA-B12 and its association with relapse
after cyclophosphamide treatment. Associations
with HLA have been observed in a number of im-
munopathologic disorders, and several mechanisms
are possible [10]. HLA also influences the syn-
drome which develops in atopic individuals [11].
The greater tendency to relapse in those with a his-
tory of eczema than in those with other atopic
symptoms may suggest that relapses are linked with
the susceptibility to the generalized blood-born
manifestations of atopy rather than with the suscep-
tibility to local manifestations at the site of antigen
entry. Consistent with this is the demonstration of
circulating antigen-antibody complexes during re-
lapse of SRNS [12], but other explanations are pos-
sible. For example, a poor cortisol response to
ACTH after treatment of the first episode of SRNS
predicts subsequent relapse [13]; if corticosteroid-
induced adrenal suppression were linked to HLA-
B12 it could explain the association of HLA-Bl2
with relapse.
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Appendix
The effect of the following variables on time-to-relapse was
investigated: x1, age (years) at time of treatment; x2, HLA-Bl2 (I
positive, 0 negative); x3, atopy on questionnaire (I posi-
tive, 0 negative); x4, skin tests (I = positive, 0 negative).
Cox's regression and Life Table model [9] in the form
X(t) X0(t) exp(f31x1 + /32x2 + /33x3 + $4x4)
was fitted to the data. A(t), termed the "force of mortality" or
"instantaneous failure rate" is the probability of relapse at time
t, given freedom from relapse up to t for a patient with independ-
ent variable values x1, x2, x3, and x4. The effect of each of the
variables is directly reflected in the values of the corresponding
coefficients /3k, /32, /33, and /3, estimates of which are obtained by
the method of maximum likelihood [14]. Details of this model
fitting are given in the top line of Appendix Table I. Tests of
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significance concerning the coefficients were conducted by fitting
reduced models with each of the variables omitted in turn: the
results of this standard likelihood ratio test procedure are pre-
sented in Appendix Table I. For details regarding the use of
these statistical procedures in the analysis of general time-to-re-
sponse data, see Kay [IS].
The coefficient /32 (HLA-B12) was significantly different from
zero (P < 0.05) and J3 (atopy on questionnaire) suggestively so
(0.05 < P< 0.10), whereas /3 (age) and /34 (prick tests) were not.
That is, patients with HLA-B12 or with positive results to the
atopy questionnaire have shorter times-to-relapse after taking in-
to account the other variables.
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